Insulin Glargine

Brand names: Lantus · Active ingredient: Insulin Glargine

In short: Insulin Glargine-aldy is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use Insulin Glargine-aldy is not recommended for the treatment of diabetic ketoacidosis.

Forms & strengthsInjection: 100 units/mL (U-100) a clear and colorless solution available as: 3 mL single-patient-use Insulin Glargine-aldy prefilled pen
LabelLanexa Biologics, LLC
Label updatedOct 20, 2026

What is Insulin Glargine used for?

Insulin Glargine-aldy is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

Limitations of Use

Insulin Glargine-aldy is not recommended for the treatment of diabetic ketoacidosis.

Insulin Glargine dosage

Always check insulin labels before administration. This product is LANGLARA (insulin glargine-aldy)

.

Visually inspect Insulin Glargine-aldy prefilled pens for particulate matter and discoloration prior to administration. Only use if the solution is clear and colorless with no visible particles.

Administer Insulin Glargine-aldy subcutaneously into the abdominal area, thigh, or deltoid, and rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy and localized cutaneous amyloidosis. Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis

.

During changes to a patient's insulin regimen, increase the frequency of blood glucose monitoring

.

Do not administer intravenously or via an insulin pump.

Do not dilute or mix Insulin Glargine-aldy with any other insulin or solution.

The Insulin Glargine-aldy prefilled pen dials in 1-unit increments.

Use Insulin Glargine-aldy prefilled pen with caution in patients with visual impairment who may rely on audible clicks to dial their dose.

Administer Insulin Glargine-aldy subcutaneously once daily at any time of day but at the same time every day.

Individualize and adjust the dosage of Insulin Glargine-aldy based on the patient's metabolic needs, blood glucose monitoring results and glycemic control goal.

Dosage adjustments may be needed with changes in physical activity, changes in meal patterns (i.e., macronutrient content or timing of food intake), during acute illness, or changes in renal or hepatic function. Dosage adjustments should only be made under medical supervision with appropriate glucose monitoring

.

In patients with type 1 diabetes, Insulin Glargine-aldy must be used concomitantly with short-acting insulin.

Recommended Starting Dosage in Patients with Type 1 Diabetes

The recommended starting dosage of Insulin Glargine-aldy in patients with type 1 diabetes is approximately one-third of the total daily insulin requirements. Use short-acting, premeal insulin to satisfy the remainder of the daily insulin requirements.

Recommended Starting Dosage in Patients with Type 2 Diabetes

The recommended starting dosage of Insulin Glargine-aldy in patients with type 2 diabetes who are not currently treated with insulin is 0.2 units/kg or up to 10 units once daily.

Dosage adjustments are recommended to lower the risk of hypoglycemia when switching patients to Insulin Glargine-aldy from other insulin therapies

.

When switching from:

Once-daily Insulin Glargine (300 units/mL) to once-daily Insulin Glargine-aldy (100 units/mL), the recommended starting Insulin Glargine-aldy dosage is 80% of the insulin glargine (300 units/mL) dosage that is being discontinued. …

How to take Insulin Glargine — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Never Share a Insulin Glargine-aldy Prefilled Pen Between Patients

Advise patients that they must never share a Insulin Glargine-aldy prefilled pen with another person, even if the needle is changed. Sharing carries a risk for transmission of blood-borne pathogens

.

Hyperglycemia or Hypoglycemia

Inform patients that hypoglycemia is the most common adverse reaction with insulin. Inform patients of the symptoms of hypoglycemia (e.g., impaired ability to concentrate and react). This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery. Advise patients who have frequent hypoglycemia or reduced or absent warning signs of hypoglycemia to use caution when driving or operating machinery

.

Advise patients that changes in insulin regimen can predispose to hyperglycemia or hypoglycemia and that changes in insulin regimen should be made under close medical supervision

. …

Warnings & precautions

Do not take this medicine if: Insulin Glargine-aldy is contraindicated:

During episodes of hypoglycemia

In patients with hypersensitivity to any insulin glargine product or any of the inactive ingredients of Insulin Glargine-aldy

Insulin Glargine-aldy prefilled pens must never be shared between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.

Changes in an insulin regimen (e.g., insulin strength, manufacturer, type, injection site or method of administration) may affect glycemic control and predispose to hypoglycemia

or hyperglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis have been reported to result in hyperglycemia; and a sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia

.

Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of blood glucose monitoring. Advise patients who have repeatedly injected into areas of lipodystrophy or localized cutaneous amyloidosis to change the injection site to unaffected areas and closely monitor for hypoglycemia. For patients with type 2 diabetes, dosage adjustments of concomitant oral and antidiabetic products may be needed.

Hypoglycemia is the most common adverse reaction associated with insulins, including insulin glargine products. Severe hypoglycemia can cause seizures, may be life-threatening or cause death. Hypoglycemia can impair concentration ability and reaction time; this may place the patient and others at risk in situations where these abilities are important (e.g., driving or operating other machinery).

Hypoglycemia can happen suddenly, and symptoms may differ in each patient and change over time in the same patient. …

Insulin Glargine side effects

The following adverse reactions are discussed elsewhere:

Hyperglycemia or Hypoglycemia with Changes in Insulin Regimen

Hypoglycemia

Hypoglycemia Due to Medication Errors

Hypersensitivity Reactions

Hypokalemia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trial of another drug and may not reflect the rates observed in practice.

The data in Table 1 reflect the exposure of 2,327 patients with type 1 diabetes to insulin glargine or NPH in Studies A, B, C, and D

. The type 1 diabetes population had the following characteristics: the mean age was 39 years, 54% were male, and mean body mass index (BMI) was 25.1 kg/m

2. Ninety-seven percent were White, 2% were Black or African American and less than 1% were Asian. Approximately 3% of the patients in studies B and C were Hispanic.

The data in Table 2 reflect the exposure of 1,563 patients with type 2 diabetes to insulin glargine or NPH in Studies E, F, and G

. The type 2 diabetes population had the following characteristics: the mean age was 59 years, 58% were male, and mean BMI was 29.2 kg/m

2. Eighty-seven percent were White, 8% were Black or African American and 3% were Asian. Approximately 9% of patients in Study F were Hispanic. …

Drug interactions

Table 8 includes clinically significant drug interactions with Insulin Glargine-aldy.

Drugs that May Increase the Risk of Hypoglycemia

Drugs: | Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), sulfonamide antibiotics, GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.

Intervention: | Dosage reductions and increased frequency of glucose monitoring may be required when Insulin Glargine-aldy is coadministered with these drugs.

Drugs that May Decrease the Blood Glucose Lowering Effect of Insulin Glargine-aldy

Drugs: | Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones.

Intervention: | Dosage increases and increased frequency of glucose monitoring may be required when Insulin Glargine-aldy is coadministered with these drugs. …

About this medicine

Insulin Glargine-aldy is a long-acting human insulin analog produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of

Pichia pastoris. Insulin Glargine-aldy differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Insulin Glargine-aldy has a molecular weight of 6063 Da.

Insulin Glargine-aldy (insulin glargine-aldy) injection is a sterile, clear and colorless solution for subcutaneous use in a 3 mL single-patient use prefilled pen.

Each mL contains 100 units of insulin glargine-aldy and the inactive ingredients: glycerin (17 mg), metacresol (2.7 mg), zinc oxide (37.34 mcg), and Water for Injection, USP. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. Insulin Glargine-aldy has a pH of approximately 4.

How it works: The primary activity of insulin, including insulin glargine products, is regulation of glucose metabolism. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 536a4b0a-4b7c-2d23-e063-6294a90a7b7c. Read the full official label on DailyMed.

Related medicines

Atorvastatin Metformin Losartan Semaglutide Empagliflozin Glipizide Insulin Lispro Dulaglutide